Stabilization of Exametazime for Leucocyte Labelling: A New Approach using Tin Enhancement

  • C. Solanki
  • D. J. Li
  • A. Wong
  • C. Sampson
Part of the NATO ASI Series book series (NSSA, volume 262)


We have examined the effect of the addition of two different stannous chloride formulations on the levels of primary lipophilic 99mTc exametazime. In the first study a solution containing 20 μg Sncl2 2H2 O was prepared (“in house”method) and used over a two week period. The mean level of radiochemical purity was 41% (range 11%-60%, n=6). In the second study a kit formulation containing 6.6 μg of Sncl2 2H2O/ml was prepared freshly each day. The mean radiochemical purity of 99mTc exametazime was 87% (range 68%-93%, n=5).


Radiochemical Purity Labelling Efficiency Stannous Chloride Gentisic Acid Primary Complex 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Roddie ME, Peters AM, Danpure H et al. Imaging with Tc-99m HM-PAO lablled leucocytes. Radiology; 166: 767–772 (1988).PubMedGoogle Scholar
  2. 2.
    Mortelmans L. Clinical usefulness of Tc-99m HM-PAO labelled white blood cell imaging in abscesses. Clin Nucl Med; 14: 127–130 (1989).PubMedCrossRefGoogle Scholar
  3. 3.
    Becker W. Radiolabeled granulocytes in inflamatory bowel disease: diagnostic possibilities and clinical indications. Ncl Med Commun; 9: 693–696 (1988).CrossRefGoogle Scholar
  4. 4.
    Scholmerich J, Schmidt E, Schichen C et al. Scintigraphic assessment of bowel involvement and disease activity in Crohn’s disease using Tc-99m Hm.PAO as a leucocyte label. Gastroenterology; 95: 1287–1293 (1988).PubMedGoogle Scholar
  5. 5.
    Roddie ME, Peters AM, Osma S et al. Osteomyelitis. Nucl Med Commun; 9: 713–718 (1988).PubMedCrossRefGoogle Scholar
  6. 6.
    Peters AM. Sepsis. Nucl Med Commun; 9: 719–723 (1988).PubMedCrossRefGoogle Scholar
  7. 7.
    Reynolds JH, Graham D, Smith FW. Imaging inflammation with Tc-99m Hm-PAO labelled leucocytes. Clin Radiol; 42: 195–198 (1990).PubMedCrossRefGoogle Scholar
  8. 8.
    Al Janabi MA, Solanki K, Critchley M et al. Radioleucoscintigraphy in osteoarthritis. Is there an inflammatory component?. Nucl Med Comm; 13: 706–712 (1992).Google Scholar
  9. 9.
    Hung JC, Volkert WA, Holmens RA. Stabilization of Tc-99m-D, L-HMPAO using gentisic acid. Nucl Med Biol; 16: 675–680 (1989).Google Scholar
  10. 10.
    Lang J, Barbarics E, Lazar J at al. Effects of labelling conditions and formulations of kit on in vitro stability of Tc-99m-D, L-HMPAO. Eur J Nucl Med; 15: 424 (1989).Google Scholar
  11. 11.
    Ballinger J. Preparation of Tc-99m HMPAO. J Nucl Med, 31: 1892 (1990).Google Scholar
  12. 12.
    Hawkins T, Reeder A, Keavey PM et al. The long term stability reconstituted exametazime: a clinical and laboratory evaluation. Nucl Med Commun; 12: 1045–1055 (1991).PubMedCrossRefGoogle Scholar
  13. 13.
    Amersham international plc: ceretec package insert.Google Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • C. Solanki
    • 1
  • D. J. Li
    • 1
  • A. Wong
    • 1
  • C. Sampson
    • 1
  1. 1.Department of Nuclear MedicineAddenbrookes HospitalCambridgeUK

Personalised recommendations